Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Global Blood Ther (NQ: GBT )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 4, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Global Blood Ther

< Previous 1 2 3 4 Next >
Biotech Stocks Well-Positioned For The Fourth Quarter
The path of interest rates is clearer for 2022 and the FED is closer to a pause early next year as it calibrates its response from a hammer approach so far. 
Via Talk Markets
These Were the Five Best And Worst Performing Mid-Cap Stocks In August 2022
We have used the August return data from finviz.com to come up with the five best and worst performing mid-cap stocks in August 2022. 
Via Talk Markets
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why. 
Via Investor's Business Daily
Global Blood Therapeutics's Return On Capital Employed Overview
Benzinga Pro data, Global Blood Therapeutics (NASDAQ:GBT) reported Q2 sales of $71.55 million. Earnings fell to a loss of $82.47 million, resulting in a 1.29% decrease from last quarter. 
Via Benzinga
Where Global Blood Therapeutics Stands With Analysts
  Within the last quarter, Global Blood Therapeutics (NASDAQ:GBT) has observed the following analyst ratings: 
Via Benzinga
Pfizer Inks $5.4 Billion Deal To Acquire Global Blood Therapeutics
The deal adds to Pfizer's efforts to tackle sickle cell disease. 
Via Investor's Business Daily
Pfizer Scoops Up Sickle Disease Player For $5B
Via Benzinga
Global Blood Therapeutics's Return On Capital Employed Overview
Global Blood Therapeutics (NASDAQ:GBT) brought in sales totaling $71.55 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 1.29%, resulting in a loss of $82.47... 
Via Benzinga
After Pfizer, Now Novo Nordisk Beefs Up Its Sickle Cell Portfolio With Forma Therapeutics Deal
Via Benzinga
GLOBAL BLOOD THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Global Blood Therapeutics, Inc. - GBT
From Kahn Swick & Foti, LLC
Via Business Wire
10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And Others
These names are benefitting from M&A, clinical data and promising regulatory actions. 
Via Investor's Business Daily
Blistering-Hot Biotech Shopping Spree Continues: Alcon To Buy Aerie For $770 Million
The biopharma buying spree continued Tuesday with glaucoma drugs maker Aerie. 
Via Investor's Business Daily
Stock Market Rally Rises On Inflation Data; Nvidia, Micron, Tesla, Disney In Focus: Weekly Review
The major indexes continued to advance, despite some key warnings. 
Via Investor's Business Daily
Analysts See Softened Timelines For CRISPR Therapeutics' Sickle Cell Candidate In US
Via Benzinga
8 Analysts Have This to Say About Global Blood Therapeutics
  Within the last quarter, Global Blood Therapeutics (NASDAQ:GBT) has observed the following analyst ratings: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2022
  
Via Benzinga
Global Blood Therapeutics: Q2 Earnings Insights
  Global Blood Therapeutics (NASDAQ:GBT) reported its Q2 earnings results on Monday, August 8, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
GLOBAL BLOOD THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Global Blood Therapeutics, Inc. - GBT
From Kahn Swick & Foti, LLC
Via Business Wire
Why These Pfizer Analysts Like The Global Blood Therapeutics Deal
Pfizer Inc. (NYSE: PFE) shares were trading lower Monday after the drugmaker announced a $5.4-billion bid to acquire blood disorder drugmaker Global Blood Therapeutics Inc (NASDAQ: GBT). 
Via Benzinga
TBLT, RDBX: The Top 5 Short Squeeze Stocks to Watch This Week
Short squeeze stocks are still a hot topic this week and we're listing five of the shares investors will want to keep an eye on! 
Via InvestorPlace
GBT Stock Alert: Pfizer Is Officially Acquiring Global Blood Therapeutics
GBT stock is already rallying on takeover talk. Now that Pfizer has confirmed the buyout, Global Blood Therapeutics is red hot. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022
  
Via Benzinga
Global Blood (GBT) Stock Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Global Blood Therapeutics, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – GBT
From Halper Sadeh LLP
Via Business Wire
Benzinga Before The Bell: Elon Musk Confirms Tesla AI Day Part 2, Dogecoin Scam, BioNTech Q2 Earnings Shocker And Other Top Financial Stories Monday, August 8
CNBC Celsius Withdraws Motion To Rehire CFO 
Via Benzinga
iRobot, Fox Factory, TripAdvisor And Some Other Big Gainers From Friday
U.S. stocks closed mixed on Friday following the release of jobs data for July. Here is the list of some big stocks moving higher in the previous session. 
Via Benzinga
Why Quoin Pharmaceuticals Plunged Over 62%; Here Are 120 Biggest Movers From Friday
Gainers 
Via Benzinga
Small Cap Biotechs Perk Up On Dealmaking
With M&A picking up we would think smaller deals make sense for large cap biopharma to expand pipelines and complement technology. 
Via Talk Markets
12 Health Care Stocks Moving In Friday's Intraday Session
  
Via Benzinga
A Preview Of Global Blood Therapeutics's Earnings
Global Blood Therapeutics (NASDAQ:GBT) is set to give its latest quarterly earnings report on Monday, 2022-08-08. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Pfizer Is Reportedly In 'Advanced Talks' To Buy Global Blood Therapeutics For $5 Billion
Shares of Pfizer's rumored takeover target have rocketed for two days running. 
Via Investor's Business Daily
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.